<DOC>
	<DOCNO>NCT00162201</DOCNO>
	<brief_summary>Study ass change synovial tissue treatment Abatacept subject RA remain background disease modify anti-arthritis medication fail previous therapy anti-TNF ( tumor necrose factor ) block agent .</brief_summary>
	<brief_title>An Exploratory Study Changes Synovial Immune Responses Following BMS-188667 Therapy Subjects With Active Rheumatoid Arthritis Background DMARDs Who Have Failed Anti-TNF Therapy</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>RA least 1 year Clear clinical sign active RA 1 knee joint Meet ARA ( 1987 ) criterion diagnosis RA ACR ( 1991 ) criterion RA functional class I , II , III Inadequate clinical response minimum 3 month therapy antiTNFblocking agent Taking background DMARDs minimum 3 month stable dos least 28 day Serious bacterial infection last 3 month History TB History cancer within 5 year Evidence latent active bacterial viral infection Intraarticular corticosteroid within 3 month Exposure live vaccine Exposure CTLA4Ig BMS188667 Treatment immunoadsorption column ( ) , mycophenolate mofetil , leflunomide , anakinra , cyclosporine , etanercept , adalimumab , infliximab , azathioprine , oral parenteral gold , Dpenacillamine , calcineurin inhibitor , cyclophosphamide alkylating agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>